Phillip Munson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Phillip Munson has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Arthur Oubrie
Lead Pharma, Kloosterstraat, Oss, the Netherlands
45 shared publications - Avinash Sahu
Department of Computer Science, The University of New Mexico
45 shared publications - Bas Jansen
Lead Pharma, Kloosterstraat, Oss, the Netherlands
45 shared publications - Chenfei Wang
Tongji University
45 shared publications - Clifford A. Meyer
Department of Data Science, Dana-Farber Cancer Institute , Boston, MA
45 shared publications - Collin Tokheim
Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts
45 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
ESRRA inhibition is associated with immune infiltrations and proinflammatory signaling in patient tumors.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
ESRRA inhibition is associated with immune infiltrations and proinflammatory signaling in patient tumors.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S13 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Kaplan–Meier plots showing progression-free survival and overall survival differences for patients receiving anti-PD1 between the low-risk and high-risk groups defined by the median value of deepBTAS.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Kaplan–Meier plots showing progression-free survival and overall survival differences for patients receiving anti-PD1 between the low-risk and high-risk groups defined by the median value of deepBTAS.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
ESRRA inhibition induces antitumor immunity in vivo.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
ESRRA inhibition induces antitumor immunity in vivo.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S15 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Evaluation of scRNA-BipotentR (BipotentR without bulk-tumor sub-module).
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S15 from Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Evaluation of scRNA-BipotentR (BipotentR without bulk-tumor sub-module).